Skip to content

PTHS PTHS Amended Sato license — Contractual Obligation

Other product segments

Reedy Creek Purchase Agreement
$20.87M
ZELSUVMI Royalty Agreement
$10.2M
Xepi Royalty Agreement
$2.22M
Channel Products Royalty Agreement
$0

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNLicense — Contract Liabilities
$90M
10x Genomics, Inc. logo
TXGSoftware Development — Contractual obligation
$18.6M-5.1%
Blue Owl Technology Finance Corp. logo
OTFOther Contractual Commitments
$2.24B
Monro, Inc. logo
MNROOther Contractual Commitments
$93.86M-4.1%
Texas Community Bancshares, Inc. logo
TCBSOther Contractual Commitments
$0
McDonald's logo
MCDOther Contractual Commitments
$14.42B+7.3%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:ContractualObligation.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's amended sato license — contractual obligation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's amended sato license — contractual obligation?
PTHS (PTHS) reported amended sato license — contractual obligation of $1.15M in Q1 2026.
What does amended sato license — contractual obligation mean?
This reflects the total gross contractual commitment arising from the amended Sato licensing agreement. It encompasses all future payments, including royalties and milestone fees, that the company is legally obligated to pay to the licensor. This metric provides a view of the total potential financial exposure tied to this specific intellectual property.